Key result
The UKGRIS trial is a cluster-randomized protocol of 3000 patients designed to evaluate whether the GRACE risk score improves guideline-indicated care and 12-month outcomes in NSTEACS.
Why the study?
Guidelines recommend the GRACE risk score for NSTEACS risk stratification, but its impact on adherence to guideline-indicated treatments and adverse clinical outcomes is unknown.
Does management according to the GRACE risk score improve the use of guideline-indicated therapies and reduce adverse clinical outcomes in patients hospitalised with NSTEACS?
RCT (n=3,000)
1:1 cluster randomized
Yes
Does management according to the GRACE risk score improve the use of guideline-indicated therapies and reduce adverse clinical outcomes in patients hospitalised with NSTEACS?
This protocol outlines a cluster-randomized trial to evaluate whether implementing the GRACE risk score improves guideline adherence and clinical outcomes in patients with NSTEACS.
No takes yet. Share an insight, caveat, or question.
GRACE-guided NSTEACS care remains unproven; UKGRIS RCT will test effects on guideline adherence and 12-month outcomes.
Everett et al. (2019) conducted an RCT in non-ST elevation acute coronary syndrome (n=3,000). GRACE risk score and associated treatment recommendations vs. standard care was evaluated on use of guideline-indicated therapies, and the composite of cardiovascular death, non-fatal myocardial infarction, new onset heart failure hospitalisation or cardiovascular readmission. The UKGRIS trial is a cluster-randomized protocol of 3000 patients designed to evaluate whether the GRACE risk score improves guideline-indicated care and 12-month outcomes in NSTEACS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: